Opinion|Videos|April 11, 2025
Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis
Panelists discuss how long-term data confirm the sustained efficacy and safety of IL-17 inhibitors in psoriasis. Secukinumab (Bissonnette, 2018; Langley, 2022) and ixekizumab (Blauvelt, 2021) show durable PASI responses over 5 years. Brodalumab’s 5-year pharmacovigilance (Lebwohl, 2024) and 120-week data (Puig, 2020) support its long-term use. Bimekizumab’s 4-year data (Blauvelt, 2024; Gordon, 2024) demonstrate continued efficacy, with 5-year results anticipated at AAD 2025.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What do we know about the long-term safety and efficacy of IL-17 inhibitors in psoriasis?
- Secukinumab 5-year data (Bissonnette, 2018;
Langley, 2022 ) - Ixekizumab 5-year data (Blauvelt, 2021)
- Brodalumab 5-year pharmacovigilance (Lebwohl, 2024); 120-week data (Puig, 2020)
- Bimekizumab 4-year data (Blauvelt, 2024; Gordon, 2024); 5-year data expected at AAD 2025
- Secukinumab 5-year data (Bissonnette, 2018;
Advertisement
Related to this article
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
By week 36, combination therapy altered 482 proteins and 467 genes vs 140 and 16 with ixekizumab alone in exploratory TOGETHER-PsO data.
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
5